

Pier Luigi Meroni

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4020902/pier-luigi-meroni-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

524
papers

29,306
citations

77
h-index

150
g-index

570
ext. papers

34,512
ext. citations

6.6
avg, IF

6.83
L-index

#	Paper	IF	Citations
524	Myocardial involvement in anti-phospholipid syndrome: Beyond acute myocardial infarction. <i>Autoimmunity Reviews</i> , 2021 , 102990	13.6	
523	Role of antiphospholipid antibodies in the diagnosis of antiphospholipid syndrome. <i>Journal of Translational Autoimmunity</i> , 2021 , 4, 100134	4.1	3
522	Integrative epigenomics in Sjögren's syndrome reveals novel pathways and a strong interaction between the HLA, autoantibodies and the interferon signature. <i>Scientific Reports</i> , 2021 , 11, 23292	4.9	2
521	Autoantibodies and SARS-CoV2 infection: The spectrum from association to clinical implication: Report of the 15th Dresden Symposium on Autoantibodies.. <i>Autoimmunity Reviews</i> , 2021 , 21, 103012	13.6	10
520	2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	5
519	EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies. <i>Rheumatology</i> , 2021 , 60, 1114-1124	3.9	19
518	Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. <i>Arthritis Care and Research</i> , 2021 , 73, 1490-1504	4.7	13
517	Long-term Outcome of Children Born to Women with Autoimmune Rheumatic Diseases: A Multicentre, Nationwide Study on 299 Randomly Selected Individuals. <i>Clinical Reviews in Allergy and Immunology</i> , 2021 , 1	12.3	0
516	Microarray evaluation of allergen-specific IgE in eosinophilic granulomatosis with polyangiitis. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1247-1248	2.4	0
515	A new molecular classification to drive precision treatment strategies in primary Sjögren's syndrome. <i>Nature Communications</i> , 2021 , 12, 3523	17.4	15
514	Low Preconception Complement Levels Are Associated with Adverse Pregnancy Outcomes in a Multicenter Study of 260 Pregnancies in 197 Women with Antiphospholipid Syndrome or Carriers of Antiphospholipid Antibodies. <i>Biomedicine</i> , 2021 , 9,	4.8	4
513	Anti-phospholipid antibodies and reproductive failures. <i>American Journal of Reproductive Immunology</i> , 2021 , 85, e13258	3.8	6
512	Antibodies and diagnostic tests in antiphospholipid syndrome 2021 , 565-574		1
511	Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1073-1085	9.5	27
510	Complement activation and endothelial perturbation parallel COVID-19 severity and activity. <i>Journal of Autoimmunity</i> , 2021 , 116, 102560	15.5	57
509	Cerebrospinal fluid phosphorylated neurofilament heavy chain and chitotriosidase in primary lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 , 92, 221-223	5.5	2
508	An elevated polyclonal free light chain level reflects a strong interferon signature in patients with systemic autoimmune diseases. <i>Journal of Translational Autoimmunity</i> , 2021 , 4, 100090	4.1	5

507	Multi-organ complement deposition in COVID-19 patients 2021 ,		9
506	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	10
505	EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	19
504	Biologics During Pregnancy and Breastfeeding Among Women With Rheumatic Diseases: Safety Clinical Evidence on the Road. <i>Frontiers in Pharmacology</i> , 2021 , 12, 621247	5.6	5
503	Multiple-Organ Complement Deposition on Vascular Endothelium in COVID-19 Patients. <i>Biomedicines</i> , 2021 , 9,	4.8	13
502	Correspondence on "European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance" by Aringer. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	3
501	Antiphospholipid Antibody Assays in 2021: Looking for a Predictive Value in Addition to a Diagnostic One. <i>Frontiers in Immunology</i> , 2021 , 12, 726820	8.4	4
500	Consumption of complement in a 26-year-old woman with severe thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. <i>Journal of Autoimmunity</i> , 2021 , 124, 102728	15.5	1
499	COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION).. <i>Lupus</i> , 2021 , 9612033211062523	2.6	3
498	Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2020 , 16, 715-726	8.1	28
497	Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2020 , 22, 265	5.7	5
496	Complement activation in patients with COVID-19: A novel therapeutic target. <i>Journal of Allergy and Clinical Immunology</i> , 2020 , 146, 215-217	11.5	150
495	Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors. <i>Autoimmunity Reviews</i> , 2020 , 19, 102509	13.6	8
494	IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases. <i>Scientific Reports</i> , 2020 , 10, 11010	4.9	2
493	In utero exposure to Azathioprine in autoimmune disease. Where do we stand?. <i>Autoimmunity Reviews</i> , 2020 , 19, 102525	13.6	13
492	Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled	2.4	3
491	Development of a certified reference material for anti- β -glycoprotein I IgG γ -commutability studies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020 , 59, 325-332	5.9	2
490	Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome 2020 ,		8

489	The Complement System in the Pathophysiology of Pregnancy and in Systemic Autoimmune Rheumatic Diseases During Pregnancy. <i>Frontiers in Immunology</i> , 2020 , 11, 2084	8.4	13
488	Antiphospholipid autoantibody detection is important in all patients with systemic autoimmune diseases. <i>Journal of Autoimmunity</i> , 2020 , 115, 102524	15.5	4
487	Anti-atherogenic Modification of Serum Lipoprotein Function in Patients with Rheumatoid Arthritis after Tocilizumab Treatment, a Pilot Study. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	6
486	The IMMENSE Study: The Interplay Between iMMune and ENdothelial Cells in Mediating Cardiovascular Risk in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2020 , 11, 572876	8.4	4
485	Complement Activation and Thrombin Generation by MBL Bound to α -Glycoprotein I. <i>Journal of Immunology</i> , 2020 , 205, 1385-1392	5.3	7
484	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1333-1339	2.4	16
483	Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome. <i>Frontiers in Immunology</i> , 2020 , 11, 584241	8.4	86
482	Standardization procedure for flow cytometry data harmonization in prospective multicenter studies. <i>Scientific Reports</i> , 2020 , 10, 11567	4.9	11
481	Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 , 6, 104-114	6.4	14
480	ANA as an entry criterion for the classification of SLE. <i>Autoimmunity Reviews</i> , 2019 , 18, 102400	13.6	29
479	Targeting CD34 cells of the inflamed synovial endothelium by guided nanoparticles for the treatment of rheumatoid arthritis. <i>Journal of Autoimmunity</i> , 2019 , 103, 102288	15.5	14
478	Lung Disease in Antiphospholipid Syndrome. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2019 , 40, 278-294	3.9	8
477	Certified reference material against PR3 ANCA IgG autoantibodies. From development to certification. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019 , 57, 1197-1206	5.9	5
476	EULAR recommendations for the management of antiphospholipid syndrome in adults. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1296-1304	2.4	312
475	Hormones and Autoimmunity 2019 , 181-190		
474	Personalized Medicine in Autoimmunity 2019 , 619-624		
473	Blood Cell-Bound C4d as a Marker of Complement Activation in Patients With the Antiphospholipid Syndrome. <i>Frontiers in Immunology</i> , 2019 , 10, 773	8.4	14
472	Neuroimmune crosstalk in the pathophysiology of hypertension. <i>Nature Reviews Cardiology</i> , 2019 , 16, 476-490	14.8	34

471	First Report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry). <i>Frontiers in Cardiovascular Medicine</i> , 2019 , 6, 11	5.4	26
470	Interleukin-17/Interleukin-21 and Interferon- γ -producing T cells specific for β 2-Glycoprotein I in atherosclerosis inflammation of systemic lupus erythematosus patients with antiphospholipid syndrome. <i>Haematologica</i> , 2019 , 104, 2519-2527	6.6	15
469	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1553-1570	9.5	31
468	The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases. <i>Autoimmunity Reviews</i> , 2019 , 18, 406-414	13.6	39
467	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1151-1159	2.4	344
466	Triple Antiphospholipid (aPL) Antibodies Positivity Is Associated With Pregnancy Complications in aPL Carriers: A Multicenter Study on 62 Pregnancies. <i>Frontiers in Immunology</i> , 2019 , 10, 1948	8.4	17
465	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1400-1412	9.5	488
464	Effectiveness and Tolerability of Repeated Courses of Viscosupplementation in Symptomatic Hip Osteoarthritis: A Retrospective Observational Cohort Study of High Molecular Weight Medium Molecular Weight Hyaluronic Acid No Viscosupplementation. <i>Frontiers in Pharmacology</i> , 2019 , 10, 1007	5.6	8
463	IFI16 and Anti-IFI16 as Novel Biomarkers for Sjogren's Syndrome: Preliminary Data. <i>Proceedings (mdpi)</i> , 2019 , 35, 30	0.3	
462	A WHO Reference Reagent for lupus (anti-dsDNA) antibodies: international collaborative study to evaluate a candidate preparation. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1677-1680	2.4	9
461	Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies. <i>Autoimmunity Reviews</i> , 2019 , 18, 164-176	13.6	27
460	New insight into antiphospholipid syndrome: antibodies to β 2-glycoprotein I-domain 5 fail to induce thrombi in rats. <i>Haematologica</i> , 2019 , 104, 819-826	6.6	21
459	Detection of anti-adalimumab antibodies in a RA responsive cohort of patients using three different techniques. <i>Analytical Biochemistry</i> , 2019 , 566, 133-138	3.1	5
458	P2X7 receptor restrains pathogenic Tfh cell generation in systemic lupus erythematosus. <i>Journal of Experimental Medicine</i> , 2019 , 216, 317-336	16.6	49
457	"Disease knowledge index" and perspectives on reproductive issues: A nationwide study on 398 women with autoimmune rheumatic diseases. <i>Joint Bone Spine</i> , 2019 , 86, 475-481	2.9	17
456	Sex and Management of Rheumatoid Arthritis. <i>Clinical Reviews in Allergy and Immunology</i> , 2019 , 56, 333-345	14.5	49
455	Pitfalls of antinuclear antibody detection in systemic lupus erythematosus: the positive experience of a national multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e50	2.4	15
454	Unending story of the indirect immunofluorescence assay on HEp-2 cells: old problems and new solutions?. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e46	2.4	28

453	The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository. <i>Arthritis Care and Research</i> , 2019 , 71, 134-141	4.7	23
452	Reply to: Vaccination for hepatitis B virus in an Australian pre-biologic population with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37, 164	2.2	
451	Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 639-646	7.6	48
450	The incidence of cardiovascular events in Italian patients with systemic lupus erythematosus is lower than in North European and American cohorts: implication of disease-associated and traditional risk factors as emerged by a 16-year retrospective GIRRCs study: GIRRCs=Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale. <i>Medicine (United States)</i> , 2018 , 97, e0370	1.8	4
449	Standardization of autoimmune testing - is it feasible?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018 , 56, 1734-1742	5.9	11
448	The treatment of anti-phospholipid syndrome: A comprehensive clinical approach. <i>Journal of Autoimmunity</i> , 2018 , 90, 1-27	15.5	46
447	Beyond thrombosis: Anti- β GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome. <i>Journal of Autoimmunity</i> , 2018 , 90, 76-83	15.5	41
446	Baseline ultrasound examination as possible predictor of relapse in patients affected by juvenile idiopathic arthritis (JIA). <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1426-1431	2.4	25
445	Diagnostic laboratory tests for systemic autoimmune rheumatic diseases: unmet needs towards harmonization. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018 , 56, 1743-1748	5.9	17
444	Management of Thrombotic Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2018 , 44, 419-426	5.3	21
443	Inflammatory Joint Disorders and Neutrophilic Dermatoses: a Comprehensive Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2018 , 54, 269-281	12.3	10
442	Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. <i>Journal of Autoimmunity</i> , 2018 , 86, 1-8	15.5	57
441	Flares After Withdrawal of Biologic Therapies in Juvenile Idiopathic Arthritis: Clinical and Laboratory Correlates of Remission Duration. <i>Arthritis Care and Research</i> , 2018 , 70, 1046-1051	4.7	18
440	Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with Methotrexate) in Patients with Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results from the CZP-SPEED Study. <i>Advances in Therapy</i> , 2018 , 35, 1153-1168	4.1	5
439	Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications. <i>Frontiers in Immunology</i> , 2018 , 9, 1388	8.4	28
438	Gene expression profiling identifies distinct molecular signatures in thrombotic and obstetric antiphospholipid syndrome. <i>Journal of Autoimmunity</i> , 2018 , 93, 114-123	15.5	13
437	Primary antiphospholipid syndrome and antiphospholipid syndrome associated to systemic lupus: Are they different entities?. <i>Autoimmunity Reviews</i> , 2018 , 17, 739-745	13.6	15
436	Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?. <i>Nature Reviews Rheumatology</i> , 2018 , 14, 433-440	8.1	61

435	Vitamin D and Anti-Phospholipid Antibody Syndrome: A Comprehensive Review. <i>Open Rheumatology Journal</i> , 2018 , 12, 248-260	0.2	3
434	Immunologic Abnormalities in the Antiphospholipid Syndrome 2018 , 235-247		
433	Therapy for antiphospholipid miscarriages: Throwing the baby out with the bathwater?. <i>American Journal of Reproductive Immunology</i> , 2018 , 79, e12792	3.8	1
432	Prevalence and Thrombotic Risk Assessment of Anti- β Glycoprotein I Domain I Antibodies: A Systematic Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2018 , 44, 466-474	5.3	41
431	Immediate treatment with tumour necrosis factor inhibitors in synthetic disease-modifying anti-rheumatic drugs-naïve patients with rheumatoid arthritis: results of a modified Italian Expert Consensus. <i>Rheumatology</i> , 2018 , 57, vii32-vii41	3.9	1
430	HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2018 , 17, 1153-1168	13.6	43
429	Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts. <i>Arthritis Research and Therapy</i> , 2018 , 20, 187	5.7	15
428	Thrombosis and Anti-phospholipid Syndrome: a 5-Year Update on Treatment. <i>Current Rheumatology Reports</i> , 2018 , 20, 44	4.9	5
427	Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying anti-rheumatic drugs. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36, 317-328	2.2	27
426	Successful sequential therapy with rituximab and belimumab in patients with active systemic lupus erythematosus: a case series. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36, 643-647	2.2	17
425	EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 476-485	2.4	375
424	Mechanisms of Action of the Antiphospholipid Antibodies. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017 , 12, 31-46	0.3	0
423	β Glycoprotein I Recognition Drives Th1 Inflammation in Atherosclerotic Plaques of Patients with Primary Antiphospholipid Syndrome. <i>Journal of Immunology</i> , 2017 , 198, 2640-2648	5.3	28
422	Comparing Originator Biologics and Biosimilars: A Review of the Relevant Issues. <i>Clinical Therapeutics</i> , 2017 , 39, 1026-1039	3.5	17
421	Does APS Impact Women's Fertility?. <i>Current Rheumatology Reports</i> , 2017 , 19, 33	4.9	13
420	Detection of early endothelial damage in patients with Raynaud's phenomenon. <i>Microvascular Research</i> , 2017 , 113, 22-28	3.7	16
419	Mechanisms of Antiphospholipid Antibody-Mediated Pregnancy Morbidity 2017 , 117-143		3
418	Longterm Outcome of Patients with Primary Antiphospholipid Syndrome: A Retrospective Multicenter Study. <i>Journal of Rheumatology</i> , 2017 , 44, 1165-1172	4.1	35

4 ¹⁷	Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences. <i>Clinical Rheumatology</i> , 2017 , 36, 1747-1755	3.9	23
4 ¹⁶	Change Over Time in the Pattern of Clinical Response to First-line Biologic Drugs in Patients with Rheumatoid Arthritis: Observational Data in a Real-life Setting. <i>Journal of Rheumatology</i> , 2017 , 44, 262-263	4.1	3
4 ¹⁵	Evaluation of Endothelial Function by Flow-Mediated Dilatation: a Comprehensive Review in Rheumatic Disease. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2017 , 65, 463-475	4	24
4 ¹⁴	Oxidation of β -glycoprotein I associates with IgG antibodies to domain I in patients with antiphospholipid syndrome. <i>PLoS ONE</i> , 2017 , 12, e0186513	3.7	8
4 ¹³	Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. <i>PLoS ONE</i> , 2017 , 12, e0169830	3.7	15
4 ¹²	Limited cutaneous systemic sclerosis skin demonstrates distinct molecular subsets separated by a cardiovascular development gene expression signature. <i>Arthritis Research and Therapy</i> , 2017 , 19, 156	5.7	9
4 ¹¹	Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconversion?. <i>Autoimmunity Reviews</i> , 2017 , 16, 1109-1114	13.6	11
4 ¹⁰	Differences in serum and synovial CD4+ T cells and cytokine profiles to stratify patients with inflammatory osteoarthritis and rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017 , 19, 103	5.7	53
4 ⁰⁹	Cutaneous Manifestations of ANCA-Associated Small Vessels Vasculitis. <i>Clinical Reviews in Allergy and Immunology</i> , 2017 , 53, 428-438	12.3	42
4 ⁰⁸	Development of a Certified Reference Material for myeloperoxidase-anti-neutrophil cytoplasmic autoantibodies (MPO-ANCA). <i>Clinica Chimica Acta</i> , 2017 , 467, 48-50	6.2	15
4 ⁰⁷	Evaluation of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results of an international multicentre study. <i>Lupus</i> , 2017 , 26, 266-276	2.6	38
4 ⁰⁶	The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2017 , 52, 401-423	12.3	37
4 ⁰⁵	Eight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis. <i>Arthritis Care and Research</i> , 2017 , 69, 867-874	4.7	23
4 ⁰⁴	Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. <i>Immunologic Research</i> , 2017 , 65, 17-24	4.3	58
4 ⁰³	Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests 2017 , 171-187		2
4 ⁰²	Serum chemerin in systemic sclerosis: a novel marker of early diffuse disease?. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35 Suppl 106, 223-224	2.2	2
4 ⁰¹	IL-22 capacitates dermal fibroblast responses to TNF in scleroderma. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1697-705	2.4	31
4 ⁰⁰	Epigenetics and Systemic Lupus Erythematosus: Unmet Needs. <i>Clinical Reviews in Allergy and Immunology</i> , 2016 , 50, 367-76	12.3	23

399	What is known about pediatric antiphospholipid syndrome?. <i>Expert Review of Hematology</i> , 2016 , 9, 977-858	11
398	Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers. <i>Arthritis Research and Therapy</i> , 2016 , 18, 111	5.7 24
397	Pyoderma gangrenosum and its syndromic forms: evidence for a link with autoinflammation. <i>British Journal of Dermatology</i> , 2016 , 175, 882-891	4 97
396	Cardiovascular Issues in SLE. <i>Rare Diseases of the Immune System</i> , 2016 , 133-145	0.2
395	Challenges and treatment options for rheumatoid arthritis during pregnancy. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1539-47	4 24
394	Recognition and management of antiphospholipid syndrome. <i>Current Opinion in Rheumatology</i> , 2016 , 28, 51-9	5.3 20
393	Anti-beta-2 glycoprotein I epitope specificity: from experimental models to diagnostic tools. <i>Lupus</i> , 2016 , 25, 905-10	2.6 27
392	From autoantibody research to standardized diagnostic assays in the management of human diseases - report of the 12th Dresden Symposium on Autoantibodies. <i>Lupus</i> , 2016 , 25, 787-96	2.6 14
391	The challenges of lupus anticoagulants. <i>Expert Review of Hematology</i> , 2016 , 9, 389-400	2.8 24
390	Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. <i>British Journal of Ophthalmology</i> , 2016 , 100, 782-6	5.5 63
389	The light and the dark sides of Interleukin-10 in immune-mediated diseases and cancer. <i>Cytokine and Growth Factor Reviews</i> , 2016 , 30, 87-93	17.9 72
388	Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15 years. <i>Autoimmunity Reviews</i> , 2016 , 15, 162-6	13.6 34
387	Towards a better understanding of the clinical association of anti-DFS70 autoantibodies. <i>Autoimmunity Reviews</i> , 2016 , 15, 198-201	13.6 40
386	IL-10-producing forkhead box protein 3-negative regulatory T cells inhibit B-cell responses and are involved in systemic lupus erythematosus. <i>Journal of Allergy and Clinical Immunology</i> , 2016 , 137, 318-321.e5	11.5 27
385	Feasibility, acceptability and construct validity of EQ-5D in systemic sclerosis. <i>Swiss Medical Weekly</i> , 2016 , 146, w14394	3.1 6
384	Antibodies and Diagnostic Tests in Antiphospholipid Syndrome 2016 , 495-501	
383	Antiglutamate Receptor Antibodies and Cognitive Impairment in Primary Antiphospholipid Syndrome and Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2016 , 7, 5	8.4 22
382	Measuring IgA Anti- β -Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome. <i>PLoS ONE</i> , 2016 , 11, e0156407	3.7 50

381	Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry. <i>Arthritis Care and Research</i> , 2016 , 68, 432-9	4.7	57
380	Maternal outcome in pregnant women with lupus nephritis. A prospective multicenter study. <i>Journal of Autoimmunity</i> , 2016 , 74, 194-200	15.5	55
379	Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery. <i>Blood</i> , 2016 , 127, 365-7	2.2	51
378	Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study. <i>Journal of Autoimmunity</i> , 2016 , 74, 6-12	15.5	69
377	Prevention & treatment of obstetrical complications in APS: Is hydroxychloroquine the Holy Grail we are looking for?. <i>Journal of Autoimmunity</i> , 2016 , 75, 1-5	15.5	17
376	First steps in the standardization of immunoglobulin IgG myeloperoxidase-anti-neutrophil cytoplasmic antibody measurements. <i>Clinical and Experimental Immunology</i> , 2016 , 183, 193-205	6.2	5
375	Prothrombotic biomarkers in patients with rheumatoid arthritis: the beneficial effect of IL-6 receptor blockade. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 451-8	2.2	14
374	Prevention of cardiovascular disease in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2015 , 14, 952-69	13.6	57
373	Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism. <i>Arthritis and Rheumatology</i> , 2015 , 67, 1155-64	9.5	76
372	The challenging definition of naïve patient for biological drug use. <i>Autoimmunity Reviews</i> , 2015 , 14, 543-63.6	3.6	6
371	Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β -glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2196-204	9.5	68
370	Systemic vasculitis and pregnancy: a multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies. <i>Autoimmunity Reviews</i> , 2015 , 14, 686-91	13.6	33
369	Purified IgG from patients with obstetric but not IgG from non-obstetric antiphospholipid syndrome inhibit trophoblast invasion. <i>American Journal of Reproductive Immunology</i> , 2015 , 73, 390-401	3.8	22
368	A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study. <i>Microvascular Research</i> , 2015 , 102, 19-24	3.7	11
367	Is there a need for new thresholds to define remission and low disease activity by Disease Activity Score 28 calculated with C reactive protein? Real life data from a local registry. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, e5	2.4	8
366	Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1011-8	2.4	369
365	Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis. <i>Immunologic Research</i> , 2015 , 61, 24-30	4.3	42
364	Choroidal impairment and macular thinning in patients with systemic sclerosis: the acute study. <i>Microvascular Research</i> , 2015 , 97, 31-6	3.7	37

363	Update on the pathogenesis and treatment of the antiphospholipid syndrome. <i>Current Opinion in Rheumatology</i> , 2015 , 27, 476-82	5.3	29
362	Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management-An Insight into Future Approaches. <i>Journal of Immunology Research</i> , 2015 , 2015, 951424	4.5	37
361	Uniphasic Blanching of the Fingers, Abnormal Capillaroscopy in Nonsymptomatic Digits, and Autoantibodies: Expanding Options to Increase the Level of Suspicion of Connective Tissue Diseases beyond the Classification of Raynaud's Phenomenon. <i>Journal of Immunology Research</i> , 2015 , 2015, 371960	4.5	12
360	New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: A systematic analysis. <i>Autoimmunity Reviews</i> , 2015 , 14, 812-29	13.6	25
359	Sparing effect of hemiplegia on skin fibrosis and microvascular involvement: reports of two cases of systemic sclerosis and review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2015 , 44, 597-601	5.3	3
358	Second generation analysis of antinuclear antibody (ANA) by combination of screening and confirmatory testing. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015 , 53, 1991-2002	5.9	20
357	Position paper of Italian rheumatologists on the use of biosimilar drugs. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, 1-4	2.2	21
356	Reliability and validity of the Italian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, S55-60	2.2	7
355	Hypomethylating agent 5-aza-2'-deoxycytidine (DAC) ameliorates multiple sclerosis in mouse models. <i>Journal of Cellular Physiology</i> , 2014 , 229, 1918-25	7	38
354	New tests to detect antiphospholipid antibodies: anti-domain I beta-2-glycoprotein-I antibodies. <i>Current Rheumatology Reports</i> , 2014 , 16, 402	4.9	39
353	Tumour necrosis factor antagonists in the treatment of rheumatoid arthritis: an immunological perspective. <i>BioDrugs</i> , 2014 , 28 Suppl 1, S5-13	7.9	20
352	Antiendothelial Cell Antibodies 2014 , 723-729		
351	Rheumatoid Factors 2014 , 751-760		
350	Autoantibodies [Future Trends 2014 , 825-828		1
349	Obstetric antiphospholipid syndrome: a recent classification for an old defined disorder. <i>Autoimmunity Reviews</i> , 2014 , 13, 901-8	13.6	43
348	Autoantibodies to coagulation factors: from pathophysiology to diagnosis and therapy. <i>Autoimmunity Reviews</i> , 2014 , 13, 40-8	13.6	42
347	New oral anticoagulants in thrombotic antiphospholipid syndrome. <i>Lupus</i> , 2014 , 23, 1279-82	2.6	31
346	International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 17-23	2.4	360

345	Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. <i>Arthritis Research and Therapy</i> , 2014 , 16, 209	5.7	73
344	Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 609-15	2.4	97
343	Long-term treatment with golimumab for severe uveitis. <i>Ocular Immunology and Inflammation</i> , 2014 , 22, 90-5	2.8	72
342	Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome. <i>Clinical and Experimental Immunology</i> , 2014 , 178, 48-56	6.2	144
341	Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. <i>Rheumatology</i> , 2014 , 53, 1664-8	3.9	60
340	Safety considerations when prescribing immunosuppression medication to pregnant women. <i>Expert Opinion on Drug Safety</i> , 2014 , 13, 1591-9	4.1	23
339	Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an "anchor" drug?. <i>Autoimmunity Reviews</i> , 2014 , 13, 1102-8	13.6	55
338	Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study. <i>Rheumatology</i> , 2014 , 53, 1570-7	3.9	62
337	Autoantibody profiling in APS. <i>Lupus</i> , 2014 , 23, 1262-4	2.6	12
336	Standardization of autoantibody testing: a paradigm for serology in rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2014 , 10, 35-43	8.1	59
335	The comparison of effects of biologic agents on rheumatoid arthritis damage progression is biased by period of enrollment: data from a systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2014 , 43, 730-7	5.3	8
334	β -glycoprotein I, lipopolysaccharide and endothelial TLR4: three players in the two hit theory for anti-phospholipid-mediated thrombosis. <i>Journal of Autoimmunity</i> , 2014 , 55, 42-50	15.5	42
333	VGX-1027 modulates genes involved in lipopolysaccharide-induced Toll-like receptor 4 activation and in a murine model of systemic lupus erythematosus. <i>Immunology</i> , 2014 , 142, 594-602	7.8	34
332	14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. <i>Autoimmunity Reviews</i> , 2014 , 13, 917-30	13.6	186
331	A non-complement-fixing antibody to β glycoprotein I as a novel therapy for antiphospholipid syndrome. <i>Blood</i> , 2014 , 123, 3478-87	2.2	98
330	Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study. <i>Thrombosis and Haemostasis</i> , 2014 , 112, 727-35	7	79
329	Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients. <i>Reumatismo</i> , 2014 , 65, 278-85	1.1	13
328	High IL-17E and low IL-17C dermal expression identifies a fibrosis-specific motif common to morphea and systemic sclerosis. <i>PLoS ONE</i> , 2014 , 9, e105008	3.7	27

327	Simultaneous automated screening and confirmatory testing for vasculitis-specific ANCA. <i>PLoS ONE</i> , 2014 , 9, e107743	3.7	24
326	Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy. <i>Autoimmunity</i> , 2014 , 47, 146-53	3	19
325	Update on the current recommendations and outcomes in pregnant women with antiphospholipid syndrome. <i>Expert Review of Clinical Immunology</i> , 2014 , 10, 1505-17	5.1	23
324	Toll-like receptor 4 and α glycoprotein I interaction on endothelial cells. <i>Lupus</i> , 2014 , 23, 1302-4	2.6	17
323	Association of pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) shares genetic and cytokine profiles with other autoinflammatory diseases. <i>Medicine (United States)</i> , 2014 , 93, e187	1.8	83
322	International standards for IgG and IgM anti- α glycoprotein antibody measurement. <i>Lupus</i> , 2014 , 23, 1317-9	2.6	12
321	Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. <i>Journal of Immunology Research</i> , 2014 , 2014, 315179	4.5	114
320	Novel mechanisms of action of the biologicals in rheumatic diseases. <i>Clinical Reviews in Allergy and Immunology</i> , 2014 , 47, 6-16	12.3	20
319	The Geoepidemiology of Autoimmune Liver Disease 2014 , 27-43		
318	Anti-Ro/SSA-p200 antibodies in the prediction of congenital heart block. An Italian multicentre cross-sectional study on behalf of the 'Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA) Group'. <i>Clinical and Experimental Rheumatology</i> , 2014 , 32, 848-54	2.2	12
317	Cardiovascular disease in autoimmune rheumatic diseases. <i>Autoimmunity Reviews</i> , 2013 , 12, 1004-15	13.6	179
316	Less travelled roads in clinical immunology and allergy: drug reactions and the environmental influence. <i>Clinical Reviews in Allergy and Immunology</i> , 2013 , 45, 1-5	12.3	9
315	Anti-phosphatidylserine/prothrombin antibodies: an additional diagnostic marker for APS?. <i>Immunologic Research</i> , 2013 , 56, 432-8	4.3	43
314	Ferritin in the antiphospholipid syndrome and its catastrophic variant (cAPS). <i>Lupus</i> , 2013 , 22, 1327-35	2.6	40
313	Pre-conceptual exposure to rituximab: comment on the article by Ojeda-Urbe et al. <i>Clinical Rheumatology</i> , 2013 , 32, 727-8	3.9	4
312	Antinuclear antibody test: when to order?. <i>American Journal of Medicine</i> , 2013 , 126, e17	2.4	2
311	Nailfold capillaroscopy in systemic sclerosis: data from the EULAR scleroderma trials and research (EUSTAR) database. <i>Microvascular Research</i> , 2013 , 89, 122-8	3.7	73
310	Otorhinolaryngological manifestations in granulomatosis with polyangiitis (Wegener's). <i>Autoimmunity Reviews</i> , 2013 , 12, 501-5	13.6	51

309	Cocaine-induced midline destructive lesions - an autoimmune disease?. <i>Autoimmunity Reviews</i> , 2013 , 12, 496-500	13.6	48
308	Pentraxin 3, a novel cardiovascular biomarker, is expressed in aortic specimens of patients with coronary artery disease with and without rheumatoid arthritis. <i>Cardiovascular Pathology</i> , 2013 , 22, 324-331	3.8	12
307	The kaleidoscopic manifestations of systemic vasculitis. <i>Autoimmunity Reviews</i> , 2013 , 12, 459-62	13.6	5
306	Hyperferritinemia is associated with serologic antiphospholipid syndrome in SLE patients. <i>Clinical Reviews in Allergy and Immunology</i> , 2013 , 44, 23-30	12.3	25
305	Cutting-edge issues in coronary disease and the primary antiphospholipid syndrome. <i>Clinical Reviews in Allergy and Immunology</i> , 2013 , 44, 51-6	12.3	17
304	Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet's syndrome: a comprehensive review and disease classification criteria. <i>Clinical Reviews in Allergy and Immunology</i> , 2013 , 45, 202-10	12.3	104
303	Antiphospholipid antibodies mediate autoimmunity against dying cells. <i>Autoimmunity</i> , 2013 , 46, 302-6	3	21
302	Interleukin-17A+ cell counts are increased in systemic sclerosis skin and their number is inversely correlated with the extent of skin involvement. <i>Arthritis and Rheumatism</i> , 2013 , 65, 1347-56		71
301	Antiphospholipid antibodies affect human endometrial angiogenesis: protective effect of a synthetic peptide (TIFI) mimicking the phospholipid binding site of β_2 glycoprotein I. <i>American Journal of Reproductive Immunology</i> , 2013 , 70, 299-308	3.8	27
300	Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts. <i>Arthritis Research and Therapy</i> , 2013 , 15, R151	5.7	54
299	A5.5 Antibodies against Domain I of β_2 Glycoprotein I in Antiphospholipid Antibody Syndrome. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A31.3-A32	2.4	
298	Interstitial lung disease outcomes by high-resolution computed tomography (HRCT) in Anti-Jo1 antibody-positive polymyositis patients: a single centre study and review of the literature. <i>Autoimmunity Reviews</i> , 2012 , 11, 335-40	13.6	47
297	Thromboprophylaxis in carriers of antiphospholipid antibodies (APL) without previous thrombosis: "Pros" and "Cons". <i>Autoimmunity Reviews</i> , 2012 , 11, 568-71	13.6	19
296	The X chromosome and the sex ratio of autoimmunity. <i>Autoimmunity Reviews</i> , 2012 , 11, A531-7	13.6	66
295	The role of environmental estrogens and autoimmunity. <i>Autoimmunity Reviews</i> , 2012 , 11, A493-501	13.6	76
294	The immunobiology of apotransferrin in type 1 diabetes. <i>Clinical and Experimental Immunology</i> , 2012 , 169, 244-52	6.2	5
293	International consensus guidelines on anticardiolipin and anti- β_2 -glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies. <i>Arthritis and Rheumatism</i> , 2012 , 64, 1-10		137
292	Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2012 , 12, 313-7	13.6	75

291	Primary biliary cirrhosis and Sjögren's syndrome: autoimmune epithelitis. <i>Journal of Autoimmunity</i> , 2012 , 39, 34-42	15.5	92
290	Anti-phospholipid induced murine fetal loss: novel protective effect of a peptide targeting the α glycoprotein I phospholipid-binding site. Implications for human fetal loss. <i>Journal of Autoimmunity</i> , 2012 , 38, J209-15	15.5	47
289	Standards and reference materials for the anticardiolipin and anti- α glycoprotein I assays: a report of recommendations from the APL Task Force at the 13th International Congress on Antiphospholipid Antibodies. <i>Clinica Chimica Acta</i> , 2012 , 413, 358-60	6.2	44
288	Anti-GalNAc α 3a novel anti-glycan autoantibody associated with pregnancy loss in women with antiphospholipid syndrome and in a mouse experimental model. <i>Journal of Autoimmunity</i> , 2012 , 39, 420-7	15.5	7
287	Pathophysiology of the antiphospholipid syndrome (APS). <i>Revue De Medecine Interne</i> , 2012 , 33 Suppl 2, A2-4	0.1	4
286	N-TproBNP as biomarker in systemic sclerosis. <i>Clinical Reviews in Allergy and Immunology</i> , 2012 , 43, 292-301	3.1	8
285	Low levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease. <i>Reumatismo</i> , 2012 , 64, 307-13	1.1	22
284	Brief report: successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: an Italian multicenter study. <i>Arthritis and Rheumatism</i> , 2012 , 64, 1970-7		112
283	Prolactin and autoimmunity: hyperprolactinemia correlates with serositis and anemia in SLE patients. <i>Clinical Reviews in Allergy and Immunology</i> , 2012 , 42, 189-98	12.3	44
282	Skin manifestations induced by TNF-alpha inhibitors in juvenile idiopathic arthritis. <i>Clinical Reviews in Allergy and Immunology</i> , 2012 , 42, 131-4	12.3	27
281	What is the Genetics of Antiphospholipid Antibodies/Syndrome? 2012 , 41-56		
280	Preliminary evaluation of the first international reference preparation for anticitrullinated peptide antibodies. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1388-92	2.4	15
279	Obstetric and vascular APS: same autoantibodies but different diseases?. <i>Lupus</i> , 2012 , 21, 708-10	2.6	34
278	Vitamin D and antiphospholipid syndrome. <i>Lupus</i> , 2012 , 21, 736-40	2.6	41
277	The role of biologic agents in damage progression in rheumatoid arthritis: indirect comparison of data coming from randomized clinical trials. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2012 , 4, 213-23	3.8	9
276	Primary anti-phospholipid syndrome: any role for serum complement levels in predicting pregnancy complications?. <i>Rheumatology</i> , 2012 , 51, 2186-90	3.9	27
275	Regulation of auto-antibody production by persisting auto-immune complexes on follicular dendritic cells. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, A38.1-A38	2.4	
274	Potential effect of anti-inflammatory treatment on reducing the cardiovascular risk in rheumatoid arthritis. <i>Current Vascular Pharmacology</i> , 2012 , 10, 639-46	3.3	9

273	What is the Mechanism(s) of Antiphospholipid Antibody-Mediated Pregnancy Morbidity? 2012 , 79-101		0
272	Immunotherapeutic agents for SLE 2012 , 2-6		
271	Power Doppler sonography and clinical monitoring for hyaluronic Acid treatment of rhizarthrosis: a pilot study. <i>Journal of Hand and Microsurgery</i> , 2011 , 3, 51-4	0.5	10
270	Intracerebral haemorrhage, a possible presentation in Churg-Strauss syndrome: case report and review of the literature. <i>Journal of the Neurological Sciences</i> , 2011 , 301, 107-11	3.2	16
269	Pathogenesis of antiphospholipid syndrome: understanding the antibodies. <i>Nature Reviews Rheumatology</i> , 2011 , 7, 330-9	8.1	374
268	In vivo distribution of β glycoprotein I under various pathophysiologic conditions. <i>Blood</i> , 2011 , 118, 4231-8	2.2	89
267	'Criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010. <i>Lupus</i> , 2011 , 20, 182-90	2.6	61
266	Autoimmune or auto-inflammatory syndrome induced by adjuvants (ASIA): old truths and a new syndrome?. <i>Journal of Autoimmunity</i> , 2011 , 36, 1-3	15.5	41
265	The Role of Ultrasonography in the Assessment of Skeletal Hand Involvement in Systemic Sclerosis. <i>Journal of Medical Ultrasound</i> , 2011 , 19, 141-142	0.8	1
264	Rituximab for uveitis. <i>Ophthalmology</i> , 2011 , 118, 223-4	7.3	43
263	Redistribution of the nuclear protein IFI16 into the cytoplasm of ultraviolet B-exposed keratinocytes as a mechanism of autoantigen processing. <i>British Journal of Dermatology</i> , 2011 , 164, 282-90	4.0	46
262	mTOR as a multifunctional therapeutic target in HIV infection. <i>Drug Discovery Today</i> , 2011 , 16, 715-21	8.8	84
261	Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. <i>Autoimmunity Reviews</i> , 2011 , 10, 444-54	13.6	165
260	Does polymorphysm of genes coding for pro-inflammatory mediators predict the clinical response to tnf alpha blocking agents? A review analysis of the literature. <i>Autoimmunity Reviews</i> , 2011 , 10, 460-3	13.6	17
259	Systemic sclerosis. Introduction. <i>Autoimmunity Reviews</i> , 2011 , 10, 239-40	13.6	11
258	Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. <i>Autoimmunity Reviews</i> , 2011 , 11, 35-9	13.6	64
257	Detection of anti-IFI16 antibodies by ELISA: clinical and serological associations in systemic sclerosis. <i>Rheumatology</i> , 2011 , 50, 674-81	3.9	22
256	Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 145-50	2.4	96

255	The development of a simple questionnaire to screen patients with SLE for the presence of neuropsychiatric symptoms in routine clinical practice. <i>Lupus</i> , 2011 , 20, 485-92	2.6	12
254	Anti-Eglycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their 'innocent' profile?. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 380-3	2.4	66
253	Pregnancy and reproduction in autoimmune rheumatic diseases. <i>Rheumatology</i> , 2011 , 50, 657-64	3.9	91
252	Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1083-6	2.4	122
251	Diagnostic accuracy of currently available anti-double-stranded DNA antibody assays. An Italian multicentre study. <i>Clinical and Experimental Rheumatology</i> , 2011 , 29, 50-6	2.2	29
250	Variable effects of cyclophosphamide in rodent models of experimental allergic encephalomyelitis. <i>Clinical and Experimental Immunology</i> , 2010 , 159, 159-68	6.2	19
249	Antiphospholipid antibody profile: implications for the evaluation and management of patients. <i>Lupus</i> , 2010 , 19, 432-5	2.6	23
248	Prolactin's role in the pathogenesis of the antiphospholipid syndrome. <i>Lupus</i> , 2010 , 19, 1515-9	2.6	23
247	Anti-phospholipid antibody mediated fetal loss: still an open question from a pathogenic point of view. <i>Lupus</i> , 2010 , 19, 453-6	2.6	37
246	Hand impairment in systemic sclerosis: association of different hand indices with organ involvement. <i>Scandinavian Journal of Rheumatology</i> , 2010 , 39, 393-7	1.9	11
245	Antiphospholipid antibodies affect human endometrial angiogenesis. <i>Biology of Reproduction</i> , 2010 , 83, 212-9	3.9	60
244	Type I interferon therapy and its role in autoimmunity. <i>Autoimmunity</i> , 2010 , 43, 248-54	3	22
243	Patients with antiphospholipid syndrome display endothelial perturbation. <i>Journal of Autoimmunity</i> , 2010 , 34, 105-10	15.5	59
242	The proapoptotic activity of the Interferon-inducible gene IFI16 provides new insights into its etiopathogenetic role in autoimmunity. <i>Journal of Autoimmunity</i> , 2010 , 35, 114-23	15.5	35
241	Anti-t-PA antibodies in acute myocardial infarction after thrombolysis with rt-PA. <i>European Journal of Internal Medicine</i> , 2010 , 21, 25-9	3.9	2
240	ANA screening: an old test with new recommendations. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1420-24	24	336
239	Skin autoimmunity and blood coagulation. <i>Autoimmunity</i> , 2010 , 43, 189-94	3	17
238	Comparative analysis of different specific indices of hand impairment in systemic sclerosis. <i>Journal of Rheumatology</i> , 2010 , 37, 2192-3	4.1	2

237	Fetal and Obstetric Manifestations in the Antiphospholipid Syndrome. <i>Current Rheumatology Reviews</i> , 2010 , 6, 18-24	1.6	
236	Complement activation and pregnancy failure. <i>Clinical Reviews in Allergy and Immunology</i> , 2010 , 39, 153-223	2.3	32
235	The geoeidemiology of the antiphospholipid antibody syndrome. <i>Autoimmunity Reviews</i> , 2010 , 9, A299-304	3.0	124
234	Usefulness of cardiovascular biomarkers and cardiac imaging in systemic rheumatic diseases. <i>Autoimmunity Reviews</i> , 2010 , 9, 845-8	13.6	12
233	Pregnancy in autoimmune rheumatic diseases: the importance of counselling for old and new challenges. <i>Autoimmunity Reviews</i> , 2010 , 10, 51-4	13.6	32
232	Systemic lupus erythematosus and the SLE galaxy. <i>Autoimmunity Reviews</i> , 2010 , 10, 1-2	13.6	18
231	Updating on the pathogenesis of systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2010 , 10, 3-7	13.6	145
230	Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheumatic disease. <i>Arthritis Care and Research</i> , 2010 , 62, 378-85	4.7	58
229	IRF5 is associated with primary antiphospholipid syndrome, but is not a major risk factor. <i>Arthritis and Rheumatism</i> , 2010 , 62, 1201-2		14
228	Decreased expression of heparin-binding epidermal growth factor-like growth factor as a newly identified pathogenic mechanism of antiphospholipid-mediated defective placentation. <i>Arthritis and Rheumatism</i> , 2010 , 62, 1504-12		43
227	The impact of treatment of the fetus by maternal therapy on the fetal and postnatal outcomes for fetuses diagnosed with isolated complete atrioventricular block. <i>Cardiology in the Young</i> , 2009 , 19, 282-90	4.0	25
226	European Forum on Antiphospholipid Antibodies: research in progress. <i>Lupus</i> , 2009 , 18, 924-9	2.6	3
225	European consensus statement on the terminology used in the management of lupus glomerulonephritis. <i>Lupus</i> , 2009 , 18, 257-63	2.6	109
224	European attempts for the standardisation of the antiphospholipid antibodies. <i>Lupus</i> , 2009 , 18, 913-9	2.6	35
223	Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 397-9	2.4	78
222	Association of STAT4 and BLK, but not BANK1 or IRF5, with primary antiphospholipid syndrome. <i>Arthritis and Rheumatism</i> , 2009 , 60, 2468-71		52
221	Update on antiphospholipid antibodies: clinical significance. <i>International Journal of Clinical Rheumatology</i> , 2009 , 4, 551-560	1.5	0
220	Pro-inflammatory genotype as a risk factor for aPL-associated thrombosis: Report of a family with multiple anti-phospholipid positive members. <i>Journal of Autoimmunity</i> , 2009 , 32, 60-3	15.5	21

219	Treatment with rapamycin ameliorates clinical and histological signs of protracted relapsing experimental allergic encephalomyelitis in Dark Agouti rats and induces expansion of peripheral CD4+CD25+Foxp3+ regulatory T cells. <i>Journal of Autoimmunity</i> , 2009 , 33, 135-40	15.5	62
218	Chapter 4 Mechanisms of Action of Antiphospholipid Antibodies. <i>Handbook of Systemic Autoimmune Diseases</i> , 2009 , 10, 55-67	0.3	3
217	The Ped-APS Registry: the antiphospholipid syndrome in childhood. <i>Lupus</i> , 2009 , 18, 894-9	2.6	43
216	Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 1428-32	2.4	220
215	The interplay between the antiphospholipid syndrome and systemic lupus erythematosus. <i>Autoimmunity</i> , 2009 , 42, 257-9	3	26
214	Antiphospholipid syndrome and systemic lupus erythematosus: are they separate entities or just clinical presentations on the same scale?. <i>Current Opinion in Rheumatology</i> , 2009 , 21, 495-500	5.3	40
213	Kallikreins and lupus nephritis. <i>Journal of Clinical Investigation</i> , 2009 , 119, 768-71	15.9	13
212	Effects of the immunomodulator, VGX-1027, in endotoxin-induced uveitis in Lewis rats. <i>British Journal of Pharmacology</i> , 2008 , 155, 722-30	8.6	7
211	In vitro inhibition of enterobacteria-reactive CD4+CD25- T cells and suppression of immunoinflammatory colitis in mice by the novel immunomodulatory agent VGX-1027. <i>European Journal of Pharmacology</i> , 2008 , 586, 313-21	5.3	12
210	Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity?. <i>Journal of Autoimmunity</i> , 2008 , 30, 51-7	15.5	44
209	Pathogenesis of the antiphospholipid syndrome: an additional example of the mosaic of autoimmunity. <i>Journal of Autoimmunity</i> , 2008 , 30, 99-103	15.5	56
208	Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. <i>Journal of Autoimmunity</i> , 2008 , 31, 175-9	15.5	87
207	Patients with a history of stable or unstable coronary heart disease have different acute phase responses to an inflammatory stimulus. <i>Atherosclerosis</i> , 2008 , 196, 835-40	3.1	12
206	Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. <i>Pediatrics</i> , 2008 , 122, e1100-7	7.4	151
205	Pathogenic anti-nucleosome antibodies. <i>Lupus</i> , 2008 , 17, 431-6	2.6	40
204	Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome. <i>Lupus</i> , 2008 , 17, 937-42	2.6	51
203	Are the current attempts at standardization of antiphospholipid antibodies still useful? Emerging technologies signal a shift in direction. <i>Seminars in Thrombosis and Hemostasis</i> , 2008 , 34, 356-60	5.3	19
202	Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. <i>Seminars in Thrombosis and Hemostasis</i> , 2008 , 34, 236-50	5.3	173

201	Rheumatoid arthritis: a female challenge. <i>Women's Health</i> , 2008 , 4, 195-201	3	18
200	Posttransplant ischemia-reperfusion injury in transplanted heart is prevented by a minibody to the fifth component of complement. <i>Transplantation</i> , 2008 , 86, 1445-51	1.8	22
199	Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? Yes (in some cases). <i>Internal and Emergency Medicine</i> , 2008 , 3, 201-3	3.7	16
198	Updating on the pathogenic mechanisms of the antiphospholipid antibodies-associated pregnancy loss. <i>Clinical Reviews in Allergy and Immunology</i> , 2008 , 34, 332-7	12.3	27
197	Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of toll-like receptor 4. <i>Arthritis and Rheumatism</i> , 2008 , 58, 3913-23		60
196	Accelerated Atherosclerosis in Autoimmune Diseases 2008 , 383-387		
195	Anti-beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women. <i>Journal of Thrombosis and Haemostasis</i> , 2007 , 5, 2421-8	15.4	60
194	AutoAbSC.Org -- Autoantibody Standardization Committee in 2006. <i>Autoimmunity Reviews</i> , 2007 , 6, 577-806	3.6	49
193	Chronic urticaria: a disease at a crossroad between autoimmunity and coagulation. <i>Autoimmunity Reviews</i> , 2007 , 7, 71-76	13.6	48
192	EASI - The European Autoimmunity Standardisation Initiative: a new initiative that can contribute to agreed diagnostic models of diagnosing autoimmune disorders throughout Europe. <i>Annals of the New York Academy of Sciences</i> , 2007 , 1109, 138-44	6.5	26
191	Evaluation of current methods for the measurement of serum anti double-stranded DNA antibodies. <i>Annals of the New York Academy of Sciences</i> , 2007 , 1109, 401-6	6.5	25
190	Autoantibodies against protective molecules--C1q, C-reactive protein, serum amyloid P, mannose-binding lectin, and apolipoprotein A1: prevalence in systemic lupus erythematosus. <i>Annals of the New York Academy of Sciences</i> , 2007 , 1108, 227-39	6.5	65
189	Pregnancies complicated with antiphospholipid syndrome: the pathogenic mechanism of antiphospholipid antibodies: a review of the literature. <i>Annals of the New York Academy of Sciences</i> , 2007 , 1108, 505-14	6.5	48
188	Role of the interferon-inducible gene IFI16 in the etiopathogenesis of systemic autoimmune disorders. <i>Annals of the New York Academy of Sciences</i> , 2007 , 1110, 47-56	6.5	63
187	X monosomy in female systemic lupus erythematosus. <i>Annals of the New York Academy of Sciences</i> , 2007 , 1110, 84-91	6.5	45
186	Role of anti-beta2 glycoprotein I antibodies in antiphospholipid syndrome: in vitro and in vivo studies. <i>Clinical Reviews in Allergy and Immunology</i> , 2007 , 32, 67-74	12.3	18
185	Update on pregnancy in autoimmune diseases. <i>Women's Health</i> , 2007 , 3, 417-20	3	1
184	Response to tetanus vaccination in infants exposed in utero to immunosuppressants for maternal autoimmune disorders. <i>Lupus</i> , 2007 , 16, 129-32	2.6	16

183	Anti-fibroblast antibodies detected by cell-based ELISA in systemic sclerosis enhance the collagenolytic activity and matrix metalloproteinase-1 production in dermal fibroblasts. <i>Rheumatology</i> , 2007 , 46, 1779-85	3.9	26
182	Electrocardiographic abnormalities in infants born from mothers with autoimmune diseases--a multicentre prospective study. <i>Rheumatology</i> , 2007 , 46, 1285-9	3.9	37
181	Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 2319-24	11.5	150
180	Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 1327-33	2.4	160
179	Immune function in children born to mothers with autoimmune diseases and exposed in utero to immunosuppressants. <i>Lupus</i> , 2007 , 16, 651-6	2.6	29
178	Pathogenic role of anti-beta2-glycoprotein I antibodies on human placenta: functional effects related to implantation and roles of heparin. <i>Human Reproduction Update</i> , 2007 , 13, 189-96	15.8	44
177	ANTI-ENDOTHELIAL CELL AUTOANTIBODIES 2007 , 725-731		2
176	RHEUMATOID FACTORS 2007 , 755-762		
175	Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process?. <i>Journal of Autoimmunity</i> , 2007 , 28, 160-4	15.5	67
174	Role of anti-β glycoprotein I antibodies in antiphospholipid syndrome glycoprotein I antibodies in antiphospholipid syndrome. <i>Clinical Reviews in Allergy and Immunology</i> , 2007 , 32, 67-73	12.3	
173	Transforming growth factor beta1 in the pathogenesis of autoimmune congenital complete heart block: lesson from twins and triplets discordant for the disease. <i>Arthritis and Rheumatism</i> , 2006 , 54, 356-9		23
172	A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16. <i>Arthritis and Rheumatism</i> , 2006 , 54, 3939-44		55
171	Measurement of electrical skin impedance of dermal-visceral zones as a diagnostic tool for disorders of the immune system. <i>Lupus</i> , 2006 , 15, 457-61	2.6	6
170	Impact of in utero environment on the offspring of lupus patients. <i>Lupus</i> , 2006 , 15, 801-7	2.6	34
169	European attempts to set guidelines for improving diagnostics of autoimmune rheumatic disorders. <i>Lupus</i> , 2006 , 15, 391-6	2.6	36
168	Anti-inflammatory and immunosuppressive drugs and reproduction. <i>Arthritis Research and Therapy</i> , 2006 , 8, 209	5.7	373
167	Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. <i>Arthritis Research and Therapy</i> , 2006 , 8, R3	5.7	88
166	Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). <i>Lupus</i> , 2006 , 15, 191-7	2.6	67

165	Autoantibodies and Skin Involvement in Systemic Autoimmune Diseases. <i>Handbook of Systemic Autoimmune Diseases</i> , 2006 , 29-36	0.3	1
164	International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). <i>Journal of Thrombosis and Haemostasis</i> , 2006 , 4, 295-306	15.4	4725
163	Autoantibodies and prediction of reproductive failure. <i>American Journal of Reproductive Immunology</i> , 2006 , 56, 337-44	3.8	83
162	Anti-beta-2 glycoprotein I antibodies affect Bcl-2 and Bax trophoblast expression without evidence of apoptosis. <i>Annals of the New York Academy of Sciences</i> , 2006 , 1069, 364-76	6.5	19
161	Interaction of Antiphospholipid Antibodies with Endothelial Cells 2006 , 415-426		
160	Inflammation and accelerated atherosclerosis: basic mechanisms. <i>Rheumatic Disease Clinics of North America</i> , 2005 , 31, 355-62, viii	2.4	52
159	Lupus anticoagulants and their relationship with the inhibitors against coagulation factor VIII: considerations on the differentiation between the 2 circulating anticoagulants. <i>Clinical Chemistry</i> , 2005 , 51, 1883-5	5.5	36
158	Maternal and sibling microchimerism in twins and triplets discordant for neonatal lupus syndrome-congenital heart block. <i>Rheumatology</i> , 2005 , 44, 187-91	3.9	38
157	Accelerated atherosclerosis in autoimmune rheumatic diseases. <i>Circulation</i> , 2005 , 112, 3337-47	16.7	417
156	Humoral autoimmunity against endothelium: theory or reality?. <i>Trends in Immunology</i> , 2005 , 26, 275-81	14.4	45
155	Anti-DNA antibodies: a diagnostic and prognostic tool for systemic lupus erythematosus?. <i>Autoimmunity</i> , 2005 , 38, 39-45	3	74
154	Pathogenic role of anti-beta 2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of beta 2-glycoprotein I binding to trophoblast cells and functional effects of anti-beta 2-glycoprotein I antibodies in vitro. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64, 462-7	2.4	76
153	Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. <i>Blood</i> , 2005 , 106, 2340-6	2.2	256
152	Offspring of Women with Systemic Autoimmune Diseases: Fetal and Neonatal Complications and Inheritance of Autoimmune Diseases. <i>Handbook of Systemic Autoimmune Diseases</i> , 2005 , 4, 111-121	0.3	
151	Autoimmunity and anti-TNF-alpha agents. <i>Annals of the New York Academy of Sciences</i> , 2005 , 1051, 559-605	6.9	135
150	Impaired bradykinin response to ischaemia and exercise in patients with mild congestive heart failure during angiotensin-converting enzyme treatment. Relationships with endothelial function, coagulation and inflammation. <i>British Journal of Haematology</i> , 2005 , 130, 113-20	4.5	12
149	Statins and autoimmune diseases. <i>Autoimmunity Reviews</i> , 2005 , 4, 123-9	13.6	21
148	Pregnancy and autoimmunity: maternal treatment and maternal disease influence on pregnancy outcome. <i>Autoimmunity Reviews</i> , 2005 , 4, 423-8	13.6	43

147	The long-term prognosis of renal transplantation in patients with lupus nephritis. <i>American Journal of Kidney Diseases</i> , 2005 , 45, 903-11	7.4	99
146	Statins and autoimmune diseases. <i>Lupus</i> , 2005 , 14, 765-8	2.6	18
145	Nonorgan specific autoantibodies and heart damage. <i>Lupus</i> , 2005 , 14, 656-9	2.6	18
144	X chromosome monosomy: a common mechanism for autoimmune diseases. <i>Journal of Immunology</i> , 2005 , 175, 575-8	5.3	157
143	Antiphospholipid antibodies as cause of pregnancy loss. <i>Lupus</i> , 2004 , 13, 649-52	2.6	47
142	Prevalence of autoantibodies against structure specific recognition protein 1 in systemic lupus erythematosus. <i>Lupus</i> , 2004 , 13, 463-8	2.6	5
141	Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation. <i>British Journal of Haematology</i> , 2004 , 126, 85-92	4.5	46
140	Fluvastatin treatment inhibits leucocyte adhesion and extravasation in models of complement-mediated acute inflammation. <i>Clinical and Experimental Immunology</i> , 2004 , 135, 186-93	6.2	54
139	Should our approach to the anticardiolipin assay change 20 years after its discovery?. <i>Journal of Thrombosis and Haemostasis</i> , 2004 , 2, 1074-6	15.4	6
138	Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. <i>Journal of Thrombosis and Haemostasis</i> , 2004 , 2, 1558-63	15.4	108
137	Statins and autoimmune diseases. <i>APLAR Journal of Rheumatology</i> , 2004 , 7, 278-284		1
136	Neonatal lupus syndromes. <i>APLAR Journal of Rheumatology</i> , 2004 , 7, 285-291		2
135	Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. <i>American Journal of Kidney Diseases</i> , 2004 , 43, 28-36	7.4	113
134	Anti-beta 2 glycoprotein I antibodies in centenarians. <i>Experimental Gerontology</i> , 2004 , 39, 1459-65	4.5	33
133	Innate immunity in the antiphospholipid syndrome: role of toll-like receptors in endothelial cell activation by antiphospholipid antibodies. <i>Autoimmunity Reviews</i> , 2004 , 3, 510-5	13.6	47
132	Pathogenic mechanisms of antiphospholipid syndrome: a new autoimmune disease. <i>Drug Discovery Today Disease Mechanisms</i> , 2004 , 1, 309-314		7
131	Alterations in the immune system of children from mothers treated with immunosuppressive agents during pregnancy. <i>Toxicology Letters</i> , 2004 , 149, 155-62	4.4	46
130	Endothelial cell activation by antiphospholipid antibodies. <i>Clinical Immunology</i> , 2004 , 112, 169-74	9	76

129	Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. <i>Thrombosis Research</i> , 2004 , 114, 553-8	8.2	115
128	Inflammatory response and the endothelium. <i>Thrombosis Research</i> , 2004 , 114, 329-34	8.2	62
127	Neonatal lupus and a seronegative mother. <i>Lancet, The</i> , 2004 , 363, 1038	4.0	3
126	Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients. <i>Blood</i> , 2004 , 103, 2121-6	2.2	64
125	IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 14181-6	11.5	101
124	Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis. <i>Lupus</i> , 2003 , 12, 504-7	2.6	28
123	Pregnancy complications of the antiphospholipid syndrome. <i>Autoimmunity</i> , 2003 , 36, 27-32	3	22
122	Non-organ Specific Autoimmunity Involvement in Cardiovascular Disease. <i>Handbook of Systemic Autoimmune Diseases</i> , 2003 , 1, 41-51	0.3	
121	Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. <i>Blood</i> , 2003 , 101, 3495-500	2.2	260
120	Prevalence and clinical correlations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid syndrome. <i>Journal of Clinical Immunology</i> , 2003 , 23, 377-83	5.7	44
119	Concomitant disappearance of electrocardiographic abnormalities and of acquired maternal autoantibodies during the first year of life in infants who had QT interval prolongation and anti-SSA/Ro positivity without congenital heart block at birth. <i>Arthritis and Rheumatism</i> , 2003 , 48, 266-8		45
118	Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. <i>Arthritis and Rheumatism</i> , 2003 , 48, 3272-9		125
117	Enhanced monocyte expression of tissue factor by oxidative stress in patients with antiphospholipid antibodies: effect of antioxidant treatment. <i>Journal of Thrombosis and Haemostasis</i> , 2003 , 1, 523-31	15.4	23
116	Modulation of adhesion molecule expression on endothelial cells: to be or not to be?. <i>Journal of Thrombosis and Haemostasis</i> , 2003 , 1, 2280-2	15.4	7
115	Endothelium as a target for antiphospholipid antibodies. <i>Immunobiology</i> , 2003 , 207, 29-36	3.4	34
114	Endothelium activation in the anti-phospholipid syndrome. <i>Biomedicine and Pharmacotherapy</i> , 2003 , 57, 282-6	7.5	16
113	Neonatal lupus: fetal myocarditis progressing to atrioventricular block in triplets. <i>Lupus</i> , 2003 , 12, 775-8	2.6	24
112	Endothelium and the brain in CNS lupus. <i>Lupus</i> , 2003 , 12, 919-28	2.6	90

111	The two hit hypothesis in the antiphospholipid syndrome: acute ischaemic heart involvement after valvular replacement despite anticoagulation in a patient with secondary APS. <i>Lupus</i> , 2003 , 12, 851-3	2.6	23
110	Treatment of pregnant patients with antiphospholipid syndrome. <i>Lupus</i> , 2003 , 12, 524-9	2.6	95
109	Immunological Abnormalities in the Antiphospholipid Syndrome 2002 , 271-283		1
108	Short-term prophylaxis with deoxyspergualin prevents testicular autoimmunity in mice. <i>European Journal of Pharmacology</i> , 2002 , 450, 209-12	5.3	5
107	Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. <i>Arthritis and Rheumatism</i> , 2002 , 46, 1019-27		1324
106	Immunization of naive BALB/c mice with human beta2-glycoprotein I breaks tolerance to the murine molecule. <i>Arthritis and Rheumatism</i> , 2002 , 46, 1399-404		23
105	Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2002 , 46, 1602-13		118
104	Antifibroblast antibodies from systemic sclerosis patients are internalized by fibroblasts via a caveolin-linked pathway. <i>Arthritis and Rheumatism</i> , 2002 , 46, 1595-601		32
103	Prevalence of anti-cardiolipin, anti-beta2 glycoprotein I, and anti-prothrombin antibodies in young patients with epilepsy. <i>Epilepsia</i> , 2002 , 43, 52-9	6.4	44
102	Plasma levels of soluble endothelial cell protein C receptor in patients with Wegener's granulomatosis. <i>Clinical and Experimental Immunology</i> , 2002 , 128, 187-94	6.2	19
101	The role of anti-endothelial cell antibodies in Kawasaki disease - in vitro and in vivo studies. <i>Clinical and Experimental Immunology</i> , 2002 , 130, 233-40	6.2	51
100	Are cardiovascular diseases a subspeciality of clinical immunology?. <i>Clinical Reviews in Allergy and Immunology</i> , 2002 , 23, 243-5	12.3	
99	Anti-inflammatory and immunomodulating properties of statins. An additional tool for the therapeutic approach of systemic autoimmune diseases?. <i>Clinical Reviews in Allergy and Immunology</i> , 2002 , 23, 263-77	12.3	24
98	Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study. <i>Lupus</i> , 2002 , 11, 716-21	2.6	113
97	Pathogenetic associations of maternal anti-Ro/SSA antibodies. <i>Lupus</i> , 2002 , 11, 650	2.6	5
96	Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2002 , 61, 608-11	2.4	54
95	Recent advances in antiphospholipid antibodies and antiphospholipid syndromes in pediatric populations. <i>Lupus</i> , 2002 , 11, 4-10	2.6	80
94	Peripheral blood mononuclear cell beta-endorphin concentration is decreased in chronic fatigue syndrome and fibromyalgia but not in depression: preliminary report. <i>Clinical Journal of Pain</i> , 2002 , 18, 270-3	3.5	36

93	Endothelium as a target for anti-phospholipid antibodies and for therapeutical intervention. <i>Autoimmunity Reviews</i> , 2002 , 1, 55-60	13.6	18
92	Antiphospholipid/Endothelial Cell Interaction in the Pathogenesis of the Antiphospholipid Syndrome 2002 , 79-89		0
91	Classification of anti-endothelial cell antibodies into antibodies against microvascular and macrovascular endothelial cells: the pathogenic and diagnostic implications. <i>Arthritis and Rheumatism</i> , 2001 , 44, 1484-94		97
90	Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. <i>Arthritis and Rheumatism</i> , 2001 , 44, 1832-5		360
89	Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. <i>Arthritis and Rheumatism</i> , 2001 , 44, 2870-8		227
88	Antiendothelial cell antibodies in vascular inflammation. <i>Clinical and Applied Immunology Reviews</i> , 2001 , 1, 135-146		
87	Prevention and treatment of lethal murine endotoxemia by the novel immunomodulatory agent MFP-14. <i>Antimicrobial Agents and Chemotherapy</i> , 2001 , 45, 1591-4	5.9	1
86	Human monoclonal anti-endothelial cell IgG-derived from a systemic lupus erythematosus patient binds and activates human endothelium in vitro. <i>International Immunology</i> , 2001 , 13, 349-57	4.9	39
85	Do we need an international consensus statement on classification criteria for the antiphospholipid syndrome in the paediatric population?. <i>Lupus</i> , 2001 , 10, 897-8	2.6	14
84	Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2001 , 34, 366-72	13.4	130
83	Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. <i>American Journal of Kidney Diseases</i> , 2001 , 37, 490-8	7.4	151
82	Antiphospholipid antibodies and the endothelium. <i>Rheumatic Disease Clinics of North America</i> , 2001 , 27, 587-602	2.4	44
81	Activation of the immune system and coronary artery disease: the role of anti-endothelial cell antibodies. <i>Atherosclerosis</i> , 2001 , 154, 429-36	3.1	22
80	Pathogenic mechanisms mediating antiphospholipid syndrome. <i>Current Opinion in Rheumatology</i> , 2001 , 13, 377-82	5.3	67
79	Functional Heterogeneity of Pathogenic Anti-Endothelial Cell Antibodies 2001 , 211-220		1
78	QT interval prolongation in asymptomatic anti-SSA/Ro-positive infants without congenital heart block. <i>Arthritis and Rheumatism</i> , 2000 , 43, 1049-53		85
77	The story of the murine antiendothelial monoclonal antibody BGM. From patients' bedside to laboratory bench and from animal models to patients. <i>Clinical Reviews in Allergy and Immunology</i> , 2000 , 18, 3-9	12.3	
76	Essential pathogenetic role for interferon (IFN-)gamma in concanavalin A-induced T cell-dependent hepatitis: exacerbation by exogenous IFN-gamma and prevention by IFN-gamma receptor-immunoglobulin fusion protein. <i>Cytokine</i> , 2000 , 12, 315-23	4	48

75	Overview on anticardiolipin ELISA standardization. <i>Journal of Autoimmunity</i> , 2000 , 15, 195-7	15.5	25
74	Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome. <i>Journal of Autoimmunity</i> , 2000 , 15, 237-40	15.5	126
73	Celiac disease during interferon treatment. <i>Annals of Internal Medicine</i> , 1999 , 131, 157-8	8	44
72	Failure of exogenously administered interferon-gamma or blockage of endogenous interleukin-4 with specific inhibitors to augment the incidence of autoimmune diabetes in male NOD mice. <i>Autoimmunity</i> , 1999 , 30, 71-80	3	1
71	Endorphin Concentrations Are Decreased in Peripheral Blood Mononuclear Cells of Chronic Fatigue Syndrome Patients: Comparison with Depression. <i>Journal of Musculoskeletal Pain</i> , 1999 , 7, 303-307		1
70	Endogenous interleukin-12 only plays a key pathogenetic role in non-obese diabetic mouse diabetes during the very early stages of the disease. <i>Immunology</i> , 1999 , 97, 367-70	7.8	25
69	Prevention by rolipram of concanavalin A-induced T-cell-dependent hepatitis in mice. <i>European Journal of Pharmacology</i> , 1999 , 367, 399-404	5.3	7
68	Antibodies to endothelial cells identify myocardial damage and predict development of coronary artery disease in patients with transplanted hearts. <i>Human Immunology</i> , 1999 , 60, 826-32	2.3	49
67	Multicenter evaluation study on a new HEp2 ANA screening enzyme immune assay. <i>Journal of Autoimmunity</i> , 1999 , 13, 89-93	15.5	40
66	Anti-endothelial Cell Antibodies (AECA): From a Laboratory Curiosity to Another Useful Autoantibody 1999 , 285-294		6
65	Deoxyspergualin neither counteracts lipopolysaccharide (LPS) or Staphylococcus aureus enterotoxin-B (SEB) induced lethality in mice nor does it modulate the release of tumor necrosis factor-alpha. <i>Immunology Letters</i> , 1998 , 61, 63-6	4.1	1
64	Thrombotic events in patients with systemic sclerosis treated with iloprost. <i>Arthritis and Rheumatism</i> , 1998 , 41, 559-60		16
63	Human anticardiolipin monoclonal autoantibodies cause placental necrosis and fetal loss in BALB/c mice. <i>Arthritis and Rheumatism</i> , 1998 , 41, 1026-39		79
62	Essential pathogenic role for endogenous interferon-gamma (IFN-gamma) during disease onset phase of murine experimental autoimmune orchitis. I. In vivo studies. <i>Clinical and Experimental Immunology</i> , 1998 , 111, 513-20	6.2	40
61	Anti-mitochondrial M5 type antibody represents one of the serological markers for anti-phospholipid syndrome distinct from anti-cardiolipin and anti-beta2-glycoprotein I antibodies. <i>Clinical and Experimental Immunology</i> , 1998 , 112, 144-51	6.2	25
60	Blood levels of transforming growth factor-beta 1 (TGF-beta1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-beta1b). <i>Clinical and Experimental Immunology</i> , 1998 , 113, 96-9	6.2	63
59	Differential effects of anti-beta2-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome. <i>Circulation</i> , 1998 , 97, 900-6	16.7	136
58	Characterization of murine monoclonal anti-endothelial cell antibodies (AECA) produced by idiotypic manipulation with human AECA. <i>International Immunology</i> , 1998 , 10, 861-8	4.9	20

57	Immunomodulation of murine experimental SLE-like disease by interferon-gamma. <i>Lupus</i> , 1998 , 7, 445-54	16
56	Anti-neutrophil cytoplasmic antibody-enriched IgG induces adhesion of human T lymphocytes to extracellular matrix proteins. <i>Clinical Immunology and Immunopathology</i> , 1997 , 83, 245-53	6
55	Autoimmune vasculitis: a good clinical and basic exercise. <i>Clinical Reviews in Allergy and Immunology</i> , 1997 , 15, 1-3	12-3
54	Immunosuppressive activity of 15-deoxyspergualin on normal and autoimmune peripheral blood mononuclear cells. <i>European Journal of Pharmacology</i> , 1996 , 311, 213-20	5-3 5
53	Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-beta treatment. <i>Cytokine</i> , 1996 , 8, 395-400	4 75
52	Modulation of endothelial cell function by antiphospholipid antibodies. <i>Lupus</i> , 1996 , 5, 448-50	2.6 30
51	Anti-endothelial cell IgG antibodies from patients with Wegener's granulomatosis bind to human endothelial cells in vitro and induce adhesion molecule expression and cytokine secretion. <i>Arthritis and Rheumatism</i> , 1996 , 39, 758-66	116
50	Cytokines and soluble receptor changes in the transition from primary to early chronic HIV type 1 infection. <i>AIDS Research and Human Retroviruses</i> , 1996 , 12, 325-31	1.6 30
49	Endothelial Cell Autoantibodies 1996 , 245-252	10
48	Placental thrombosis and fetal loss after passive transfer of mouse lupus monoclonal or human polyclonal anti-cardiolipin antibodies in pregnant naive BALB/c mice. <i>Scandinavian Journal of Immunology</i> , 1995 , 41, 427-32	3-4 64
47	Anti-beta 2-glycoprotein I antibodies: a marker of antiphospholipid syndrome?. <i>Lupus</i> , 1995 , 4, 122-30	2.6 148
46	Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. <i>European Journal of Endocrinology</i> , 1995 , 132, 587-93	6.5 186
45	In vitro production of type 1 and type 2 cytokines by peripheral blood mononuclear cells from high-risk HIV-negative intravenous drug users. <i>Aids</i> , 1995 , 9, 691-4	3-5 26
44	Autoantibody profile of primary sclerosing cholangitis. <i>Pathobiology</i> , 1995 , 63, 76-82	3.6 28
43	Characterization of biologically active antineutrophil cytoplasmic antibodies induced in mice. Pathogenetic role in experimental vasculitis. <i>Arthritis and Rheumatism</i> , 1995 , 38, 1375-81	54
42	Antiphospholipid antibodies and endothelial cells. <i>Lupus</i> , 1994 , 3, 267-9	2.6 12
41	Protection from experimental autoimmune diabetes in the non-obese diabetic mouse with soluble interleukin-1 receptor. <i>European Journal of Immunology</i> , 1994 , 24, 1843-7	6.1 91
40	Protection from experimental autoimmune thyroiditis in CBA mice with the novel immunosuppressant deoxyspergualin. <i>Scandinavian Journal of Immunology</i> , 1994 , 39, 333-6	3-4 9

39	The effects of thymopentin on the development of SLE-like syndrome in the MRL/lpr-lpr mouse. <i>Scandinavian Journal of Immunology</i> , 1994 , 40, 549-56	3.4	6
38	Beta-endorphin content in HIV-infected HuT78 cell line and in peripheral lymphocytes from HIV-positive subjects. <i>Peptides</i> , 1994 , 15, 769-75	3.8	14
37	Characterization of the endothelial surface proteins recognized by anti-endothelial antibodies in primary and secondary autoimmune vasculitis. <i>Clinical Immunology and Immunopathology</i> , 1994 , 70, 211-6		86
36	Antiphospholipid antibodies and risk of intrauterine late fetal death. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 1994 , 73, 389-92	3.8	24
35	TH1 and TH2 cytokine production by peripheral blood mononuclear cells from HIV-infected patients. <i>Aids</i> , 1994 , 8, 757-62	3.5	134
34	Toxicological and immune findings in workers exposed to pentachlorophenol (PCP). <i>Archives of Environmental Health</i> , 1993 , 48, 81-8		43
33	The effects of a monoclonal antibody to interferon-gamma on experimental autoimmune thyroiditis (EAT): prevention of disease and decrease of EAT-specific T cells. <i>European Journal of Immunology</i> , 1993 , 23, 275-8	6.1	79
32	Increased rate of survival in Streptococcus pneumoniae-infected rats treated with the new immunomodulator Pidotimod. <i>Scandinavian Journal of Infectious Diseases</i> , 1992 , 24, 821-3		6
31	Antibodies to endothelial cells in primary vasculitides mediate in vitro endothelial cytotoxicity in the presence of normal peripheral blood mononuclear cells. <i>Clinical Immunology and Immunopathology</i> , 1992 , 63, 267-74		59
30	Enrichment of IgG anti-DNA-producing lymphoblastoid cell lines by antigen-coated immunomagnetic beads. <i>Clinical Immunology and Immunopathology</i> , 1992 , 65, 39-44		4
29	Antimitochondrial (pyruvate dehydrogenase) autoantibodies in autoimmune rheumatic diseases. <i>Journal of Clinical Immunology</i> , 1992 , 12, 201-9	5.7	51
28	In vivo treatment with a monoclonal antibody to interferon-gamma neither affects the survival nor the incidence of lupus-nephritis in the MRL/lpr-lpr mouse. <i>Immunopharmacology</i> , 1992 , 24, 11-6		23
27	In vitro and ex vivo effect of tiaprofenic acid on human peripheral blood mononuclear cells. <i>International Journal of Immunopharmacology</i> , 1992 , 14, 1279-84		1
26	Immunopharmacological activity of cefodizime in young and elderly subjects: in vitro and ex vivo studies. <i>Infection</i> , 1992 , 20 Suppl 1, S61-3	5.8	7
25	FK-506 prevents diabetes in diabetes-prone BB/Wor rats. <i>International Journal of Immunopharmacology</i> , 1991 , 13, 1027-30		10
24	Histopathological findings in a case of systemic lupus erythematosus-associated anti-phospholipid syndrome. <i>Clinical Rheumatology</i> , 1991 , 10, 211-4	3.9	5
23	A new case of IgE myeloma. <i>Acta Haematologica</i> , 1991 , 85, 41-4	2.7	12
22	Sodium fusidate and increased remission rate of insulin-dependent diabetes mellitus. <i>Lancet, The</i> , 1991 , 337, 1292	4.0	72

21	Age-related changes of beta-endorphin and cholecystokinin in human and rat mononuclear cells. <i>Peptides</i> , 1991 , 12, 1353-6	3.8	38
20	Antiendothelial cell antibodies in primary vasculitides. <i>Contributions To Nephrology</i> , 1991 , 94, 89-97	1.6	5
19	Gastric histology and function tests in Italian patients with dermatitis herpetiformis. <i>Scandinavian Journal of Gastroenterology</i> , 1990 , 25, 357-62	2.4	5
18	Enhanced percentage of CD5+ B lymphocytes in newly diagnosed IDDM patients. <i>Immunology Letters</i> , 1990 , 23, 211-5	4.1	18
17	Prevention of diabetes in BB/Wor rats treated with monoclonal antibodies to interferon-gamma. <i>Lancet, The</i> , 1990 , 336, 319	4.0	51
16	Correlation between islet cell antibodies and anti-cytomegalovirus IgM and IgG antibodies in healthy first-degree relatives of type 1 (insulin-dependent) diabetic patients. <i>Clinical Immunology and Immunopathology</i> , 1990 , 55, 139-47		20
15	Immunopotentiating Activity of Thymopentin Treatment in Elderly Subjects 1990 , 537-550		
14	In vitro and ex vivo effect of RU41740 on human polymorphonuclear leukocyte function. <i>International Journal of Immunopharmacology</i> , 1988 , 10, 121-33		14
13	Heterogeneity of immune responsiveness in healthy elderly subjects. <i>Clinical Immunology and Immunopathology</i> , 1988 , 47, 142-51		52
12	In vivo immunopotentiating activity of thymopentin in aging humans: modulation of IL-2 receptor expression. <i>Clinical Immunology and Immunopathology</i> , 1988 , 48, 140-9		15
11	Antibodies to cardiac Purkinje cells: further characterization in autoimmune diseases and atrioventricular heart block. <i>Clinical Immunology and Immunopathology</i> , 1987 , 42, 141-50		10
10	In vivo immunopotentiating activity of thymopentin in aging humans: increase of IL-2 production. <i>Clinical Immunology and Immunopathology</i> , 1987 , 42, 151-9		42
9	Influenza vaccination with adjuvant RU41740 in the elderly. <i>Lancet, The</i> , 1987 , 1, 973	4.0	17
8	Efficacy of prednisone to induce remission in recent onset type I (insulin dependent) diabetic patients. <i>Klinische Wochenschrift</i> , 1987 , 65, 244		1
7	Immunomodulating activity of RU 41740: in vitro and in vivo studies on human lymphocytes. <i>International Journal of Immunopharmacology</i> , 1987 , 9, 185-90		18
6	Detection and further characterization of a newly described microsomal autoantibody associated with chronic delta infection. <i>Digestion</i> , 1986 , 33, 181-8	3.6	8
5	Autoantibody pattern in non-A, non-B hepatitis. <i>Infection</i> , 1984 , 12, 91-4	5.8	2
4	Anti-ribosomal ribonucleoprotein autoantibodies in systemic lupus erythematosus. <i>Journal of Clinical Immunology</i> , 1984 , 4, 45-54	5.7	20

3	Abnormalities of in vitro immunoglobulin synthesis by peripheral blood lymphocytes from patients with essential mixed cryoglobulinemia. <i>Clinical Immunology and Immunopathology</i> , 1984 , 33, 245-57		19
2	Effects of chronic heroin addiction on pituitary-thyroid function in man. <i>Journal of Endocrinological Investigation</i> , 1980 , 3, 251-5	5.2	11
1	Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases		1